New Viable CRISPR-Cas12b System for Plant Genome Engineering By UMD Researcher
CRISPR-Cas12b for Plant Genome Engineering
CRISPR-Cas12b for Plant Genome Engineering
A team of researchers at the University of Minnesota Medical School recently proved the ability to grow human-derived blood vessels in a pig–a novel approach that has the potential for providing unlimited human vessels for transplant purposes. Because these vessels were made with patient-derived skin cells, they are less likely to be rejected by the recipient, helping patients potentially avoid the need for life-long, anti-rejection drugs.
Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer, and the leading cause of cancer death worldwide. More than half of NSCLC patients die after developing metastases. There are no tests currently that would allow doctors to identify patients where more aggressive therapy could reduce mortality. Researchers at Tulane University have identified a protein on tumor-derived extracellular vesicles that indicates if a NSCLC tumor is likely to metastasize, according to a new study in Science Advances.
Researchers at the University of Campinas (UNICAMP) in São Paulo State, Brazil, have developed a computer program that analyzes molecules in blood plasma to search for biomarkers that identify individuals who are at risk of becoming overweight and developing obesity-related diseases.
Bone marrow plasma cells produce antibodies. These comprise two long and two short protein chains. The pathological proliferation of plasma cells can lead to an overproduction of the short chains. These associate to fibrils and deposit in organs. The result is fatal organ failure. A research team from the Technical University of Munich (TUM) and Heidelberg University has now identified the mutation behind the disease in a patient.
IBM Watson Health is teaming up with library and information services company EBSCO Information Services with plans to merge their digital healthcare-focused offerings into one cloud-based solution platform.
Last June, Sierra Oncology steered most of its dwindling resources towards developing a phase 3 myelofibrosis drug that it picked up from Gilead, as it searched for new ways to fund SRA737, a CHK1 inhibitor that had notched impressive early results in metastatic anogenital cancer.
Aldeyra Therapeutics has halted clinical development of two systemic disease programs to stretch out its cash runway to the end of next year. The action is intended to enable Aldeyra keep pushing its ocular disease programs through late-phase development despite its falling cash reserves.
The FDA cleared a new digital imaging platform designed to give doctors a clear peek into a person’s lung function—allowing them to diagnose different respiratory diseases by visualizing factors such as the flow of blood through the organ with each breath.
The FDA approved Roche’s diagnostic for triaging women whose primary cervical cancer screenings have tested positive for the human papillomavirus (HPV). The company’s CINtec PLUS Cytology test is designed to identify women with HPV infections who are most likely to develop cervical pre-cancers.